|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
|
AU7685894A
(en)
*
|
1993-09-07 |
1995-03-27 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7101853B2
(en)
*
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
|
ATE410182T1
(de)
*
|
1998-01-09 |
2008-10-15 |
Amylin Pharmaceuticals Inc |
Formulierungen für amylin peptidagonisten mit insulin
|
|
US6087334A
(en)
*
|
1998-08-21 |
2000-07-11 |
Amylin Pharmaceuticals, Inc. |
Anti-diabetic peptides
|
|
NZ534557A
(en)
*
|
2002-01-08 |
2007-10-26 |
Amylin Pharmaceuticals Inc |
Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
|
|
AU2003259131A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
|
BRPI0411165A
(pt)
*
|
2003-05-14 |
2006-07-11 |
Emisphere Tech Inc |
composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
|
|
WO2005014022A1
(en)
*
|
2003-07-16 |
2005-02-17 |
Develogen Aktiengesellschaft |
Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
RU2385878C2
(ru)
*
|
2004-02-11 |
2010-04-10 |
Амилин Фармасьютикалз, Инк. |
Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
|
|
CA2556923A1
(en)
*
|
2004-02-20 |
2005-09-09 |
Rinat Neuroscience Corp. |
Methods of treating obesity or diabetes using nt-4/5
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
EP2455072A1
(en)
*
|
2005-03-11 |
2012-05-23 |
Endo Pharmaceuticals Solutions Inc. |
Controlled release formulations of octreotide
|
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
|
EP1988923A1
(en)
*
|
2006-02-02 |
2008-11-12 |
Rinat Neuroscience Corp. |
Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
|
|
EP1988920A1
(en)
*
|
2006-02-02 |
2008-11-12 |
Rinat Neuroscience Corp. |
Methods for treating obesity by administering a trkb antagonist
|
|
CA2672750A1
(en)
*
|
2006-12-20 |
2008-07-03 |
Rinat Neuroscience Corporation |
Trkb agonists for treating autoimmune disorders
|
|
KR20100098628A
(ko)
*
|
2007-11-14 |
2010-09-08 |
아밀린 파마슈티칼스, 인크. |
비만 및 비만 관련 질환 및 장애의 치료 방법
|
|
UA104866C2
(uk)
*
|
2008-06-25 |
2014-03-25 |
Ендо Фармас'Ютікалз Солюшнз Інк. |
Імплантат октреотиду, який містить вивільняючу речовину
|
|
WO2009158412A2
(en)
|
2008-06-25 |
2009-12-30 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
|
CN102256618A
(zh)
|
2008-10-17 |
2011-11-23 |
赛诺菲-安万特德国有限公司 |
胰岛素和glp-1激动剂的组合
|
|
JP2009149684A
(ja)
*
|
2009-03-11 |
2009-07-09 |
Amylin Pharmaceut Inc |
アミリン作動薬ペプチド用製剤
|
|
RU2537181C2
(ru)
*
|
2009-03-12 |
2014-12-27 |
Нордик Байосайенс А/С |
Лечение диабета и метаболического синдрома
|
|
TR201809460T4
(tr)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
|
|
US20110118178A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
NZ599847A
(en)
|
2009-11-13 |
2013-09-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
US20110118180A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
WO2012028172A1
(en)
|
2010-08-30 |
2012-03-08 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
BR102013017626A2
(pt)
*
|
2013-06-14 |
2015-02-10 |
Univ Rio De Janeiro |
Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
|
|
CN106687474A
(zh)
*
|
2014-09-04 |
2017-05-17 |
诺和诺德股份有限公司 |
新型胰淀素和降钙素受体激动剂
|
|
PE20171622A1
(es)
|
2014-12-12 |
2017-11-02 |
Sanofi Aventis Deutschland |
Formulacion de relacion fija de insulina glargina/lixisenatida
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|